Jci_page_head_homepage_01 Jci_page_head_homepage_02
Luke J. Engelking, Guosheng Liang, Robert E. Hammer, Kiyosumi Takaishi, Hiroshi Kuriyama, Bret M. Evers, Wei-Ping Li, Jay D. Horton, Joseph L. Goldstein, Michael S. Brown
Published in Volume 115, Issue 9
J Clin Invest. 2005; 115(9):2489–2498 doi:10.1172/JCI25614
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2

Immunoblot (A) and lipid analysis (B) of livers from control and Insig-deficient mice. The mice used in this figure are the same as those compared in Table 2. (A) Immunoblot analysis from nuclear extract and membrane fractions obtained from mice with the following 4 genotypes: (a) Insig1f/f (designated control); (b) Insig1f/fInsig2−/−MX1-Cre (designated L-Insig1–/–Insig2–/–); (c) Insig1f/fMX1-Cre (designated L-Insig1–/–); and (d) Insig1f/fInsig2–/– (designated Insig2–/–). Each mouse was treated with 4 intraperitoneal injections of pIpC (300 μg/injection), and tissues were obtained 14 days after the final injection. Livers (n = 6) were separately pooled, and 45-μg aliquots of the pooled membrane and nuclear extract fractions were subjected to SDS-PAGE and immunoblot analysis. CREB protein and the transferrin receptor were used in the immunoblots as loading controls for the nuclear extract and membrane fractions, respectively. P, pSREBP; N, nSREBP. (B) Hepatic cholesterol and triglyceride content of control and Insig-deficient livers. Each bar represents the mean ± SEM of data from 6 mice.